TPD & Induced Proximity Summit Leaderboard
  • Wednesday, July 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 2

Remix Therapeutics to Merge With Passage Bio

Jun 25, 2026
Remix Therapeutics and Passage Bio have agreed to merge in an all-stock transaction, creating a combined biotechnology company focused on advancing RNA-targeted therapies for cancer and…
Read More...

Oura, LillyDirect Partner to Support GLP-1 Patients

Jun 25, 2026
ŌURA and LillyDirect have announced a new collaboration aimed at helping people using GLP-1 weight management medicines better manage their health through wearable technology and…
Read More...

Lilly Completes Centessa Acquisition to Advance Narcolepsy Treatments

Jun 24, 2026
Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals plc, strengthening its neuroscience pipeline with promising therapies aimed at treating narcolepsy and…
Read More...

Bayer Partners With Iambic to Accelerate AI Drug Discovery

Jun 24, 2026
Bayer has entered into a strategic drug discovery collaboration with Iambic Therapeutics to accelerate the development of new small-molecule medicines using artificial intelligence. The…
Read More...

Lonza, InduPro Partner to Advance Next-Generation Cancer Therapies

Jun 24, 2026
Lonza has entered into a new licensing agreement with biotechnology company InduPro to support the development of next-generation antibody-drug conjugate (ADC) therapies for cancer. The…
Read More...

Haisco Licenses Two Drug Candidates to Nuvectis

Jun 24, 2026
Haisco Pharmaceutical Group has signed an exclusive licensing agreement with U.S.-based biotechnology company Nuvectis, granting the company rights to develop and commercialize two of…
Read More...

Combotope, Boehringer Partner on Cancer Antibody Research

Jun 24, 2026
Combotope Therapeutics has entered into a strategic research collaboration with Boehringer Ingelheim to develop a new generation of tumor-selective antibody therapies for cancer. The…
Read More...

Abbisko, Lilly Expand Drug Discovery Partnership

Jun 24, 2026
Abbisko Therapeutics has entered into a new strategic research collaboration and license agreement with Eli Lilly and Company to discover and develop innovative medicines across…
Read More...

Boehringer Advances Phase III Cancer Precision Medicine Trials

Jun 23, 2026
Boehringer Ingelheim has announced the launch of three Phase III clinical trials aimed at advancing precision oncology for patients with some of the most aggressive forms of cancer. The…
Read More...

Voro and Alloy Partner on Safer Cancer Immunotherapies

Jun 19, 2026
Voro Therapeutics and Alloy Therapeutics have entered into a strategic research collaboration aimed at developing a new generation of cancer immunotherapies designed to improve the…
Read More...
Previous 1 2 3 4 … 936 Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
TRP Supply Chain & Manufacturing Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Zymeworks to Acquire Theravance Biopharma in $929 Million Deal
  • EMA Panel Backs Lilly’s Jaypirca for Chronic Lymphocytic Leukemia
  • Talawar Therapeutics Announces $285 Million Nasdaq Merger Deal
  • AstraZeneca, YMCA Launch National Cancer Education Partnership
  • Antares, Novartis Partner on Cancer Drug Discovery

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.